Robert E. George bought $10k of MBRX
director at Moleculin Biotech, Inc.. 14,493 shares at an average of $0.69, traded Dec 26, 2023, filed Dec 27, 2023.
Score components
- +15RoleDirector
- 0Trade size$10k at market
- +10Relative to holdingsHoldings up 8678%
- +8Price context51% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-23-035341, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 26, 2023 | POpen-market purchase Common Stock | +14,493 | $0.69 | $10k | 14,660 | Dec 27, 2023 |
Related signals
Other insiders at Moleculin Biotech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Moleculin Biotech, Inc. | Jonathan P. Foster Chief Financial Officer | $100k 270,270 shares | +1561% | |
| 56Moderate | Moleculin Biotech, Inc. | Walter Klemp V CEO and President | $250k 675,675 shares | +995% | |
| 55Moderate | Moleculin Biotech, Inc. | Jonathan P. Foster Chief Financial Officer | $20k 28,986 shares | +56% | |
| 65Notable | Moleculin Biotech, Inc. | Walter Klemp V CEO and President | $130k 188,404 shares | +38% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.